Genfit has warned work on its failed phase 3 nonalcoholic steatohepatitis (NASH) trial may continue deep into 2020, leading it to continue paying for a program that may never deliver returns.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,